2018
SUSTAINED SDV OF 84.5% ACROSS ALL ENROLLING SITES IN 2018
ON-TIME SITE REPORT DELIVERY RATE OF 93% FOR 2018 FAR SURPASSES INDUSTRY AVERAGE OF 60%
2017
DR. BRYAN DONNELLY & LOUISE THOMPSON RECIPIENTS OF THE 2017 NETWORK CHAMPION AWARD
100TH SUCCESSFUL ONCOLOGY CLINICAL TRIAL… AND NEVER RESCUED BY ANOTHER CRO
20TH ANNIVERSARY OF UNPARALLELED CANADIAN CLINICAL ONCOLOGY EXPERIENCE
2016
DR. LUCY GILBERT, RECIPIENT OF THE 2016 NETWORK CHAMPION AWARD
REVERSE FEASIBILITY 2.0 MASTER CLINICAL TRIAL AGREEMENTS NEGOTIATED WITH CANADA’S TOP CENTRE
2015
DR CRISTIANO FERRARIO, 3RD RECIPIENT OF THE NETWORK CHAMPION AWARD
REVERSE FEASIBILITY PROGRAM 5 YEAR POST LAUNCH CONFIRMS 14 WEEK ACTIVATION TIME IN CANADA
SCIMEGA INKS 13TH PHASE I/II US-ONLY STUDY EXPANSION INTO CANADA IN 18 MONTHS
2014
Dr Stephen Welch, 2nd recipient of the Network Champion Award
SCIMEGA LAUNCHES “CANADA’S ONCOLOGY COMMUNITY KEY STAKEHOLDERS” PODCAST SERIES
2013
DR QUINCY CHU,1ST RECIPIENT OF THE NETWORK CHAMPION AWARD
SCIMEGA EXPERIENCE NOW INCLUDES ALL DRUGABLE ONCOLOGY INDICATION
2012
SCIMEGA COMMITS TO HELPING SMALL AND MID SIZE BIOPHARMA OPTIMIZE ONCOLOGY TRIAL PERFORMANCE IN CANADA
2011
REVERSE FEASIBILITY PROGRAM 3 YEAR POST LAUNCH CONFIRMS 50% REDUCTION IN ACTIVATION TIME COMPARED TO INDUSTRY STANDARD
2009
REVERSE FEASIBILITY PILOT PROJECT ACTIVATES SITES IN 6 WEEKS
2008
THE REVERSE FEASIBILITY PROGRAM IS BORN
SCIMEGA’S MISSION AND PURPOSE : TO ATTRACT CUTTING EDGE CANCER TRIALS TO CANADA
2007
SCIMEGA RESEARCH WINS NATIONAL BANK SMALL BUSINESS GOLD AWARD
SCIMEGA WINS 2007 DUNAMIS AWARD FOR OUTSTANDING ACHIEVEMENT IN THE SERVICE ENTERPRISE CATEGORY
2003
SCIMEGA INKS 1ST CONTRACT WITH US BIOTECH ONCOLOGY DRUG DEVELOPPER
1998
SCIMEGA RESEARCH INKS CONTRACTS FOR ONCOLOGY TRIALS WITH EVERY MAJOR CANADIAN PHARMACEUTICAL AFFILIATE
1997
SCIMEGA RESEARCH INC WAS FOUNDED
Sign up to Canadian Oncology Clinical Trial News
Receive updates from our blog, podcasts and resource library.